EGFR and cancer: Combinatorial targeting of PAI-1 function using establishedsmall molecule PAI-1 inhibitors and genetic-based PAI-1 expression attenuation[40] coupled with disruption of EGFR signaling (e.g., with cetuximab orerlotinib) may impact, therefore, both cancer invasion and the associatedangiogenic response, particularly in the context of a TGF-β1-rich tumor microenvironment.